Our findings unveil a new strategy that combines clinically relevant anti‐angiogenic treatments with Apelin inhibition to diminish tumor growth, blood vessel density, and vessel abnormality within the tumor environment, and thus hypoxia, tumor resistance, and anti‐angiogenic therapy‐induced metastasis. This evidence concerns the gene APLN and neoplasm.